Insider Buying: Anteris Technologies Global (NASDAQ:AVR) Major Shareholder Acquires 322,940 Shares of Company Stock

by · The Cerbat Gem

Anteris Technologies Global Corp. (NASDAQ:AVR – Get Free Report) major shareholder L1 Capital Pty Ltd acquired 322,940 shares of the firm’s stock in a transaction on Thursday, October 1st. The stock was purchased at an average price of $7.60 per share, for a total transaction of $2,454,344.00. Following the completion of the transaction, the insider directly owned 5,200,767 shares in the company, valued at approximately $39,525,829.20. The trade was a 6.62% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

L1 Capital Pty Ltd also recently made the following trade(s):

  • On Wednesday, September 30th, L1 Capital Pty Ltd bought 74,286 shares of Anteris Technologies Global stock. The shares were purchased at an average price of $7.72 per share, with a total value of $573,487.92.
  • On Friday, August 28th, L1 Capital Pty Ltd sold 7,800 shares of Anteris Technologies Global stock. The stock was sold at an average price of $8.83, for a total value of $68,874.00.
  • On Tuesday, August 11th, L1 Capital Pty Ltd sold 375,815 shares of Anteris Technologies Global stock. The shares were sold at an average price of $9.30, for a total value of $3,495,079.50.
  • On Monday, August 10th, L1 Capital Pty Ltd sold 251,844 shares of Anteris Technologies Global stock. The shares were sold at an average price of $9.10, for a total value of $2,291,780.40.
  • On Thursday, August 6th, L1 Capital Pty Ltd sold 174,721 shares of Anteris Technologies Global stock. The stock was sold at an average price of $8.10, for a total value of $1,415,240.10.
  • On Tuesday, August 4th, L1 Capital Pty Ltd sold 480,608 shares of Anteris Technologies Global stock. The stock was sold at an average price of $8.30, for a total value of $3,989,046.40.
  • On Wednesday, August 5th, L1 Capital Pty Ltd sold 14,581 shares of Anteris Technologies Global stock. The shares were sold at an average price of $8.23, for a total transaction of $120,001.63.
  • On Monday, August 3rd, L1 Capital Pty Ltd sold 475,693 shares of Anteris Technologies Global stock. The shares were sold at an average price of $8.10, for a total transaction of $3,853,113.30.
  • On Friday, July 31st, L1 Capital Pty Ltd sold 48,711 shares of Anteris Technologies Global stock. The stock was sold at an average price of $8.15, for a total transaction of $396,994.65.
  • On Wednesday, July 29th, L1 Capital Pty Ltd sold 155,505 shares of Anteris Technologies Global stock. The stock was sold at an average price of $8.04, for a total transaction of $1,250,260.20.

Anteris Technologies Global Stock Down 2.1%

NASDAQ AVR traded down $0.16 during trading hours on Thursday, hitting $7.61. The company’s stock had a trading volume of 1,170,680 shares, compared to its average volume of 718,688. The stock has a fifty day moving average of $8.51 and a 200 day moving average of $7.98. Anteris Technologies Global Corp. has a twelve month low of $3.30 and a twelve month high of $11.06. The firm has a market capitalization of $741.67 million, a P/E ratio of -3.90 and a beta of 1.87.

Anteris Technologies Global (NASDAQ:AVR – Get Free Report) last issued its earnings results on Tuesday, August 11th. The company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.09). Anteris Technologies Global had a negative net margin of 4,619.27% and a negative return on equity of 77.69%. The business had revenue of $1.01 million for the quarter, compared to the consensus estimate of $1.50 million. During the same quarter in the previous year, the firm posted ($0.58) EPS. On average, analysts predict that Anteris Technologies Global Corp. will post -1.21 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts recently commented on the company. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $15.00 price objective on shares of Anteris Technologies Global in a research note on Friday, August 14th. Weiss Ratings restated a “sell (d-)” rating on shares of Anteris Technologies Global in a report on Wednesday, August 26th. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Anteris Technologies Global currently has an average rating of “Moderate Buy” and an average target price of $16.00.

Check Out Our Latest Analysis on AVR

Institutional Investors Weigh In On Anteris Technologies Global

A number of institutional investors and hedge funds have recently made changes to their positions in AVR. BlackRock Inc. acquired a new position in Anteris Technologies Global during the second quarter worth $56,846,000. Nantahala Capital Management LLC acquired a new stake in shares of Anteris Technologies Global during the 2nd quarter worth about $33,325,850. ADAR1 Capital Management LLC bought a new stake in shares of Anteris Technologies Global during the 2nd quarter worth about $30,979,000. Perceptive Advisors LLC grew its stake in Anteris Technologies Global by 104.4% in the 1st quarter. Perceptive Advisors LLC now owns 3,425,476 shares of the company’s stock valued at $19,011,000 after buying an additional 1,750,000 shares during the last quarter. Finally, Militia Capital Management LLC acquired a new position in Anteris Technologies Global in the 1st quarter valued at about $3,663,000.

About Anteris Technologies Global

(Get Free Report)

Anteris Technologies Global Corp. is a medical device company focused on developing advanced technologies for structural heart disease. Its primary product candidate is the DurAVR transcatheter heart valve, designed to treat aortic valve stenosis through a minimally invasive transcatheter aortic valve replacement procedure.

The DurAVR valve is based on Anteris’ ADAPT tissue-engineering technology and is manufactured as a single-piece valve intended to replicate the performance and natural hemodynamics of a healthy human aortic valve.

Featured Stories